GlassScriptPhysician profile
Michael Cummings Engels
NPI 1598085334
$111,332.03
in general payments reported to CMS, 2019-2025
17 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2021: $8,025 · 2022: $721 · 2023: $29K · 2024: $27K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $14K · Consulting Fee: $8,338 · Food and Beverage: $3,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,712.50 |
| Travel and Lodging | $13,829.67 |
| Consulting Fee | $8,337.50 |
| Food and Beverage | $3,496.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63,141.84 | 2019-2025 | |
| Lilly USA, LLC | $17,040.47 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $14,942.52 | 2025 | Tremfya, Stelara |
| Pfizer INC. | $8,023.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $5,138.39 | 2021-2023 | Zeposia |
| Celgene Corporation | $1,420.56 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $637.89 | 2019-2025 | Entyvio, Gattex |
| Medtronic, INC. | $233.28 | 2021-2024 | Gi Genius, Interstim |
| Covidien LP | $224.77 | 2019 | |
| Allergan, INC. | $131.15 | 2019 | |
| Ferring Pharmaceuticals INC. | $114.77 | 2019 | |
| Nestle Healthcare Nutrition INC. | $105.32 | 2023 | |
| Ucb, INC. | $57.26 | 2019 | |
| Boston Scientific Corporation | $51.22 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $21.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.82 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Engels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.